广泛耐药结核病的出现：需要新干预措施的全球卫生危机：第一部分：问题的起源和性质。
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.
机构信息
New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA.
出版信息
Clin Transl Sci. 2008 Dec;1(3):249-54. doi: 10.1111/j.1752-8062.2008.00060.x.
Abstract
Surveillance studies and outbreak investigations indicate that an extensively drug-resistant (XDR) form of tuberculosis (TB) is increasing in prevalence worldwide. In outbreak settings among HIV-infected, there is a high-case fatality rate. Better outcomes occur in HIV-uninfected, particularly if drug susceptibility test (DST) results are available rapidly to allow tailoring of drug therapy. This review will be presented in two segments. The first characterizes the problem posed by XDR-TB, addressing the epidemiology and evolution of XDR-TB and treatment outcomes. The second reviews technologic advances that may contribute to the solution, new diagnostics, and advances in understanding drug resistance and in the development of new drugs.
摘要
监测研究和疫情调查表明，广泛耐药结核病（TB）在全球的流行率正在上升。在感染艾滋病毒的疫情环境中，该病的病死率很高。在未感染艾滋病毒的情况下，结果较好，特别是如果药物敏感性试验（DST）结果能够迅速获得，从而能够调整药物治疗。本综述将分为两部分呈现。第一部分描述了广泛耐药结核病带来的问题，涉及广泛耐药结核病的流行病学和演变以及治疗结果。第二部分回顾了可能有助于解决问题的技术进展、新诊断方法以及对耐药性的理解和新药开发方面的进展。
相似文献
1
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.
Clin Transl Sci. 2008 Dec;1(3):249-54. doi: 10.1111/j.1752-8062.2008.00060.x.
2
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.
3
Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review.
J Infect. 2017 Nov;75(5):433-440. doi: 10.1016/j.jinf.2017.08.005. Epub 2017 Aug 11.
4
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: Part II: scientific advances that may provide solutions.
Clin Transl Sci. 2009 Feb;2(1):80-4. doi: 10.1111/j.1752-8062.2008.00086.x.
5
Extensively drug-resistant tuberculosis in the United States, 1993-2007.
JAMA. 2008 Nov 12;300(18):2153-60. doi: 10.1001/jama.300.18.2153.
6
Extensively drug-resistant tuberculosis.
Curr Opin Infect Dis. 2009 Apr;22(2):167-73. doi: 10.1097/qco.0b013e3283229fab.
7
Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43.
8
Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011.
Western Pac Surveill Response J. 2016 Jun 8;7(2):35-40. doi: 10.5365/WPSAR.2016.7.2.002. eCollection 2016 Apr-Jun.
9
Extensively drug-resistant tuberculosis in california, 1993-2006.
Clin Infect Dis. 2008 Aug 15;47(4):450-7. doi: 10.1086/590009.
引用本文的文献
1
Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis.
BMJ Glob Health. 2024 Apr 22;9(4):e014630. doi: 10.1136/bmjgh-2023-014630.
2
Evolution of Drug-Resistant Strains and Their Adaptation to the Human Lung Environment.
Front Microbiol. 2021 Feb 4;12:612675. doi: 10.3389/fmicb.2021.612675. eCollection 2021.
3
Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.
Int J Mol Sci. 2021 Jan 13;22(2):735. doi: 10.3390/ijms22020735.
4
Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis.
Infect Immun. 2018 Aug 22;86(9). doi: 10.1128/IAI.00009-18. Print 2018 Sep.
5
Redesign of substrate specificity and identification of the aminoglycoside binding residues of Eis from Mycobacterium tuberculosis.
Biochemistry. 2013 Jul 30;52(30):5125-32. doi: 10.1021/bi4002985. Epub 2013 Jul 16.
6
Aminoglycoside multiacetylating activity of the enhanced intracellular survival protein from Mycobacterium smegmatis and its inhibition.
Biochemistry. 2012 Jun 19;51(24):4959-67. doi: 10.1021/bi3004473. Epub 2012 Jun 5.
本文引用的文献
1
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda.
Clin Infect Dis. 2008 Nov 1;47(9):1126-34. doi: 10.1086/592252.
2
Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1075-82. doi: 10.1164/rccm.200801-132OC. Epub 2008 Aug 14.
3
Management of extensively drug-resistant tuberculosis in Peru: cure is possible.
PLoS One. 2008 Aug 13;3(8):e2957. doi: 10.1371/journal.pone.0002957.
4
Treatment outcomes in extensively resistant tuberculosis.
N Engl J Med. 2008 Aug 7;359(6):657-9. doi: 10.1056/NEJMc0706556.
5
Facing extensively drug-resistant tuberculosis--a hope and a challenge.
N Engl J Med. 2008 Aug 7;359(6):636-8. doi: 10.1056/NEJMe0804906.
6
Comprehensive treatment of extensively drug-resistant tuberculosis.
N Engl J Med. 2008 Aug 7;359(6):563-74. doi: 10.1056/NEJMoa0800106.
7
Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis.
Chest. 2008 Jul;134(1):187-92. doi: 10.1378/chest.07-1988.
8
Extensively drug-resistant tuberculosis in california, 1993-2006.
Clin Infect Dis. 2008 Aug 15;47(4):450-7. doi: 10.1086/590009.
9
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005.
10
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective.
Microb Drug Resist. 2008 Jun;14(2):133-43. doi: 10.1089/mdr.2008.0798.
Zotero 插件